MedPath

A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine

Phase 2
Recruiting
Conditions
Solid Tumours
Interventions
Registration Number
NCT06619509
Lead Sponsor
Boehringer Ingelheim
Brief Summary

This study is open to adults who participated in a previous clinical study with brigimadlin.

The goal of this study is to find out how well people with solid tumours tolerate long-term treatment with brigimadlin. Brigimadlin is a so-called MDM2 inhibitor that is being developed to treat cancer.

Participants are grouped in cohorts depending on their treatment in the previous study:

* Cohort 1a got brigimadlin and continues treatment with brigimadlin

* Cohort 1b got brigimadlin for 4 or less treatment cycles; each cycle was 3 weeks long

* Cohort 2 received a comparator and gets brigimadlin for the first time

All participants take brigimadlin as tablets once every 3 weeks at the study site. Participants in the Cohorts 1b and 2 visit the sites more frequently. At study visits, doctors check participants' health and take note of any unwanted effects. At some study visits, doctors also check the size of the tumour and whether it has spread to other parts of the body.

Participants are in the study as long as they benefit from treatment and can tolerate it.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
BrigimadlinBrigimadlin-
Primary Outcome Measures
NameTimeMethod
The primary endpoint will be the occurrence of treatment-emergent adverse events (AEs) according to CTCAE Version 5.0 during the entire treatment periodup to 9 years.

CTCAE=Common Terminology Criteria for Adverse Events

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (56)

Clinexpert Gyongyos

🇭🇺

Gyongyos, Hungary

Okayama University Hospital

🇯🇵

Okayama, Okayama, Japan

Universitätsklinikum Frankfurt

🇩🇪

Frankfurt, Germany

Sourasky Medical Center

🇮🇱

Tel-Aviv, Israel

Universitätsklinikum Tübingen

🇩🇪

Tübingen, Germany

Precision NextGen Oncology

🇺🇸

Beverly Hills, California, United States

Sarcoma Oncology Center

🇺🇸

Santa Monica, California, United States

Yale Cancer Center

🇺🇸

New Haven, Connecticut, United States

Mayo Clinic Cancer Center

🇺🇸

Jacksonville, Florida, United States

Northwestern University

🇺🇸

Chicago, Illinois, United States

Dana-Farber Cancer Institute

🇺🇸

Boston, Massachusetts, United States

Washington University School of Medicine

🇺🇸

Saint Louis, Missouri, United States

Nebraska Cancer Specialists-Omaha-69066

🇺🇸

Omaha, Nebraska, United States

Northwell Health

🇺🇸

Lake Success, New York, United States

West Cancer Center & Research Institute

🇺🇸

Germantown, Tennessee, United States

Henry-Joyce Cancer Clinic

🇺🇸

Nashville, Tennessee, United States

The University of Texas MD Anderson Cancer Center

🇺🇸

Houston, Texas, United States

Utah Cancer Specialists Cancer Center

🇺🇸

Salt Lake City, Utah, United States

Fred Hutchinson Cancer Research Center

🇺🇸

Seattle, Washington, United States

University of Wisconsin

🇺🇸

Madison, Wisconsin, United States

Sanatorio Finochietto

🇦🇷

Caba, Argentina

Prince of Wales Hospital-Randwick-66496

🇦🇺

Randwick, New South Wales, Australia

Princess Alexandra Hospital

🇦🇺

Woolloongabba, Queensland, Australia

Brussels - UNIV Saint-Luc

🇧🇪

Bruxelles, Belgium

UZ Leuven

🇧🇪

Leuven, Belgium

H.S.J. Beneficência Portuguesa - São Paulo

🇧🇷

Sao Paulo, Brazil

West China Hospital

🇨🇳

Chengdu, China

Sun Yat-Sen University Cancer Center

🇨🇳

Guangzhou, China

University Hospital Olomouc

🇨🇿

Olomouc, Czechia

Copenhagen University Hospital, Rigshospitalet

🇩🇰

København Ø, Denmark

CTR Leon Berard

🇫🇷

Lyon, France

CTR Eugène Marquis

🇫🇷

Rennes, France

Helios Klinikum Berlin-Buch

🇩🇪

Berlin, Germany

Fondazione IRCCS Istituto Nazionale dei Tumori

🇮🇹

Milano, Italy

Istituto Nazionale IRCCS Tumori Fondazione Pascale

🇮🇹

Napoli, Italy

Istituto Oncologico Veneto IRCCS

🇮🇹

Padova, Italy

National Hospital Organization Kyushu Cancer Center

🇯🇵

Fukuoka, Fukuoka, Japan

Kyushu University Hospital

🇯🇵

Fukuoka, Fukuoka, Japan

Kanagawa Cancer Center

🇯🇵

Kanagawa, Yokohama, Japan

Tohoku University Hospital

🇯🇵

Miyagi, Sendai, Japan

Osaka International Cancer Institute

🇯🇵

Osaka, Osaka, Japan

National Cancer Center Hospital

🇯🇵

Tokyo, Chuo-ku, Japan

Nederlands Kanker Instituut

🇳🇱

Amsterdam, Netherlands

Oslo Universitetssykehus HF, Radiumhospitalet

🇳🇴

Oslo, Norway

Oncology Center-Maria Sklodowska-Curie Institute

🇵🇱

Warsaw, Poland

Hospital Miguel Servet

🇪🇸

Aragon, Spain

Fundación Jiménez Díaz

🇪🇸

Madrid, Spain

Hospital Clínico San Carlos

🇪🇸

Madrid, Spain

Hospital Universitario 12 de Octubre

🇪🇸

Madrid, Spain

Hospital Universitario HM Sanchinarro

🇪🇸

Madrid, Spain

Hospital Clínico de Santiago

🇪🇸

Santiago de Compostela, Spain

Karolinska Comprehensive Cancer Center

🇸🇪

Stockholm, Sweden

University Hospital Bern/Inselspital Bern

🇨🇭

Bern, Switzerland

Taipei Veterans General Hospital

🇨🇳

Taipei, Taiwan

Addenbrooke's Hospital

🇬🇧

Cambridge, United Kingdom

The Royal Marsden Hospital, Chelsea

🇬🇧

London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath